Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer

Clinical Cancer Research - Tập 22 Số 2 - Trang 436-447 - 2016
Edmund K. Moon1, Raghuveer Ranganathan1, Evgeniy Eruslanov1, Soyeon Kim1, Kheng Newick1, Shaun O’Brien1, Albert Lo2, Xiaojun Liu3, Yangbing Zhao3, Steven Μ. Albelda1
11Division of Pulmonary, Allergy, and Critical Care, University of Pennsylvania, Philadelphia, Pennsylvania.
22Department of Animal Biology and Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
33Abramson Family Cancer Research Institute and Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Tóm tắt

AbstractPurpose: Tumor-infiltrating lymphocytes (TILs) become hypofunctional, although the mechanisms are not clear. Our goal was to generate a model of human tumor-induced TIL hypofunction to study mechanisms and to test anti-human therapeutics.Experimental Design: We transduced human T cells with a published, optimized T-cell receptor (TCR) that is directed to a peptide within the cancer testis antigen, NY-ESO-1. After demonstrating antigen-specific in vitro activity, these cells were used to target a human lung cancer line that expressed NY-ESO-1 in the appropriate HLA context growing in immunodeficient mice. The ability of anti-PD1 antibody to augment efficacy was tested.Results: Injection of transgenic T cells had some antitumor activity, but did not eliminate the tumors. The injected T cells became profoundly hypofunctional accompanied by upregulation of PD1, Tim3, and Lag3 with coexpression of multiple inhibitory receptors in a high percentage of cells. This model allowed us to test reagents targeted specifically to human T cells. We found that injections of an anti-PD1 antibody in combination with T cells led to decreased TIL hypofunction and augmented the efficacy of the adoptively transferred T cells.Conclusions: This model offers a platform for preclinical testing of adjuvant immunotherapeutics targeted to human T cells prior to transition to the bedside. Because the model employs engineering of human T cells with a TCR clone instead of a CAR, it allows for study of the biology of tumor-reactive TILs that signal through an endogenous TCR. The lessons learned from TCR-engineered TILs can thus be applied to tumor-reactive TILs. Clin Cancer Res; 22(2); 436–47. ©2015 AACR.See related commentary by Yang, p. 275

Từ khóa


Tài liệu tham khảo

Morgan, 2006, Cancer regression in patients after transfer of genetically engineered lymphocytes, Science, 314, 126, 10.1126/science.1129003

June, 2014, Engineered T cells for cancer therapy, Cancer Immunol Immunother, 63, 969, 10.1007/s00262-014-1568-1

Maus, 2014, Antibody-modified T cells: CARs take the front seat for hematologic malignancies, Blood, 123, 2625, 10.1182/blood-2013-11-492231

Brocker, 2000, Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells, Blood, 96, 1999, 10.1182/blood.V96.5.1999

Geiger, 1999, The TCR zeta-chain immunoreceptor tyrosine-based activation motifs are sufficient for the activation and differentiation of primary T lymphocytes, J Immunol, 162, 5931, 10.4049/jimmunol.162.10.5931

Viola, 1996, T cell activation determined by T cell receptor number and tunable thresholds, Science, 273, 104, 10.1126/science.273.5271.104

Schumacher, 2002, T-cell-receptor gene therapy, Nat Rev Immunol, 2, 512, 10.1038/nri841

Chodon, 2014, Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma, Clin Cancer Res, 20, 2457, 10.1158/1078-0432.CCR-13-3017

Zhang, 2014, Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor, Sci Rep, 4, 3571, 10.1038/srep03571

Chinnasamy, 2011, A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer, J Immunol, 186, 685, 10.4049/jimmunol.1001775

Zhao, 2005, Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines, J Immunol, 174, 4415, 10.4049/jimmunol.174.7.4415

Parkhurst, 2011, T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis, Mol Ther, 19, 620, 10.1038/mt.2010.272

Robbins, 2011, Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1, J Clin Oncol, 29, 917, 10.1200/JCO.2010.32.2537

Fisher, 2006, Hurdles to lymphocyte trafficking in the tumor microenvironment: implications for effective immunotherapy, Immunol Invest, 35, 251, 10.1080/08820130600745430

Chappert, 2010, Induction of T cell anergy: integration of environmental cues and infectious tolerance, Curr Opin Immunol, 22, 552, 10.1016/j.coi.2010.08.005

Zou, 2005, Immunosuppressive networks in the tumour environment and their therapeutic relevance, Nat Rev Cancer, 5, 263, 10.1038/nrc1586

Baitsch, 2012, Extended co-expression of inhibitory receptors by human CD8 T-cells depending on differentiation, antigen-specificity and anatomical localization, PLoS One, 7, e30852, 10.1371/journal.pone.0030852

Jotereau, 2012, Adoptive transfer with high-affinity TCR to treat human solid tumors: how to improve the feasibility, Target Oncol, 7, 3, 10.1007/s11523-012-0207-z

Kunert, 2013, TCR-Engineered T cells meet new challenges to treat solid tumors: choice of antigen, T cell fitness, and sensitization of tumor milieu, Front Immunol, 4, 363, 10.3389/fimmu.2013.00363

Moon, 2014, Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors, Clin Cancer Res, 20, 4262, 10.1158/1078-0432.CCR-13-2627

Reichert, 2002, Signaling abnormalities, apoptosis, and reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma, Clin Cancer Res, 8, 3137

Zhang, 2010, Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer, Cell Mol Immunol, 7, 389, 10.1038/cmi.2010.28

Lee, 1999, Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients, Nat Med, 5, 677, 10.1038/9525

Robbins, 2008, Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions, J Immunol, 180, 6116, 10.4049/jimmunol.180.9.6116

Ho, 1989, Site-directed mutagenesis by overlap extension using the polymerase chain reaction, Gene, 77, 51, 10.1016/0378-1119(89)90358-2

Carpenito, 2009, Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains, Proc Natl Acad Sci U S A, 106, 3360, 10.1073/pnas.0813101106

Vazquez-Cintron, 2010, Tumor-induced disruption of proximal TCR-mediated signal transduction in tumor-infiltrating CD8+ lymphocytes inactivates antitumor effector phase, J Immunol, 185, 7133, 10.4049/jimmunol.1001157

Schietinger, 2014, Tolerance and exhaustion: defining mechanisms of T cell dysfunction, Trends Immunol, 35, 51, 10.1016/j.it.2013.10.001

Crespo, 2013, T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment, Curr Opin Immunol, 25, 214, 10.1016/j.coi.2012.12.003

Chiou, 2005, Current concepts of tumor-infiltrating lymphocytes in human malignancies, J Reprod Immunol, 67, 35, 10.1016/j.jri.2005.06.002

Prinz, 2010, High DGK-alpha and disabled MAPK pathways cause dysfunction of human tumor-infiltrating CD8+ T cells that is reversible by pharmacologic intervention, J Immunol, 188, 5990, 10.4049/jimmunol.1103028

Rabinowich, 1996, Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin 2 therapy, Clin Cancer Res, 2, 1263

Matsuzaki, 2010, Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer, Proc Natl Acad Sci U S A, 107, 7875, 10.1073/pnas.1003345107

Wang, 2011, Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors, PLoS One, 6, e17621, 10.1371/journal.pone.0017621

Ghebeh, 2006, The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors, Neoplasia, 8, 190, 10.1593/neo.05733

Ma, 2012, Tumor-infiltrating gammadelta T lymphocytes predict clinical outcome in human breast cancer, J Immunol, 189, 5029, 10.4049/jimmunol.1201892

Matsuda, 1995, Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease, Int J Cancer, 61, 765, 10.1002/ijc.2910610605

Sato, 2005, Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer, Proc Natl Acad Sci U S A, 102, 18538, 10.1073/pnas.0509182102

Robbins, 2015, A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T cell receptor: Long term follow up and correlates with response, Clin Cancer Res, 21, 1019, 10.1158/1078-0432.CCR-14-2708

Osanto, 2000, Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line, Hum Gene Ther, 11, 739, 10.1089/10430340050015635

Germeau, 2005, High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens, J Exp Med, 201, 241, 10.1084/jem.20041379

Wang, 2014, Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity, Cancer Immunol Res, 2, 154, 10.1158/2326-6066.CIR-13-0027

Okazaki, 2006, The PD-1-PD-L pathway in immunological tolerance, Trends Immunol, 27, 195, 10.1016/j.it.2006.02.001

Fourcade, 2010, Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients, J Exp Med, 207, 2175, 10.1084/jem.20100637

Sakuishi, 2010, Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity, J Exp Med, 207, 2187, 10.1084/jem.20100643

Grosso, 2009, Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells, J Immunol, 182, 6659, 10.4049/jimmunol.0804211

John, 2013, Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells, Clin Cancer Res, 19, 5636, 10.1158/1078-0432.CCR-13-0458

Jungbluth, 2001, Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues, Int J Cancer, 92, 856, 10.1002/ijc.1282

Wolchok, 2013, Nivolumab plus ipilimumab in advanced melanoma, N Engl J Med, 369, 122, 10.1056/NEJMoa1302369

Alcantar-Orozco, 2013, Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer, Hum Gene Ther Methods, 24, 310, 10.1089/hgtb.2013.022

Volk, 2012, Comparison of three humanized mouse models for adoptive T cell transfer, J Gene Med, 14, 540, 10.1002/jgm.2652

Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690

Thông tin
Thông tin xuất bản

Clinical Cancer Research

Tập 22 Số 2

436-447

Thông tin tác giả